Reference:WMA Declaration of Helsinki 2024 Paragraph 17: Difference between revisions
From GxPlex
gxplex>GxPlexBot Import from GxPlex Excel |
Gxplex admin (talk | contribs) m 1 revision imported Β |
||
| (4 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:WMA Declaration of Helsinki 2024 | ||
| | |module=4 | ||
| | |unit=4.2.1 | ||
| | |scope=G | ||
| | |doc_part=Paragraph 17 | ||
| | |language=EN | ||
| | |entry_by=Florian Adragna | ||
|contributors= | |||
Β | |tags=TAG-00176-Ris-erh ++ TAG-00051-Eth-ngs ++ TAG-00177-Ben-koB ++ TAG-00025-Sub-mer | ||
|tags_display=[[Glossary:TAG-00176-Ris-erh|Risk]], [[Glossary:TAG-00051-Eth-ngs|Ethics]], [[Glossary:TAG-00177-Ben-koB|Benefit-risk]], [[Glossary:TAG-00025-Sub-mer|Trial participant]] | |||
Β | |comment=Careful risk assessment required before human research | ||
|content=17. All medical research involving human participants must be preceded by careful assessment of predictable risks and burdens to the individuals and groups involved in the research in comparison with foreseeable benefits to them and to other individuals or groups affected by the condition under investigation. | |||
|- | |||
|- | |||
|- | |||
| Β | |||
| | |||
| | |||
Β | |||
17. All medical research involving human participants must be preceded by careful assessment of predictable risks and burdens to the individuals and groups involved in the research in comparison with foreseeable benefits to them and to other individuals or groups affected by the condition under investigation. | |||
Measures to minimize the risks and burdens must be implemented. The risks and burdens must be continuously monitored, assessed, and documented by the researcher. | Measures to minimize the risks and burdens must be implemented. The risks and burdens must be continuously monitored, assessed, and documented by the researcher. | ||
}} | |||
Latest revision as of 13:50, 16 July 2026
| Document information | |
|---|---|
| Reference | WMA Declaration of Helsinki 2024 |
| Validity area | WMA |
| Scope(s) | G |
| Document name | Declaration of Helsinki |
| Version / Revision | 2024 |
| Status | Current |
| Document type | International guideline |
| Language(s) | EN |
| Description | Declaration of Helsinki
Medical Research Involving Human Participants The Declaration of Helsinki (DoH) is the World Medical Associationβs (WMA) best-known policy statement. The first version was adopted in 1964 and has been amended seven times since, most recently at the General Assembly in October 2024. The current (2024) version is the only official one; all previous versions* have been replaced and should not be used or cited except for historical purposes. The WMA would like to thank all those who submitted comments and suggestions for the most recent revision of the DoH. |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 4 β Unit 4.2.1 |
| Scope | G |
| Document part | Paragraph 17 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Risk, Ethics, Benefit-risk, Trial participant |
Content
17. All medical research involving human participants must be preceded by careful assessment of predictable risks and burdens to the individuals and groups involved in the research in comparison with foreseeable benefits to them and to other individuals or groups affected by the condition under investigation.
Measures to minimize the risks and burdens must be implemented. The risks and burdens must be continuously monitored, assessed, and documented by the researcher.
